Hoth Therapeutics is rebranding as Rocket One to focus on low-power, radiation-tolerant AI chip infrastructure for orbital and defense applications [1].
This shift represents a complete pivot from biotechnology to the space-tech sector. The move allows the company to enter the high-growth market of orbital computing and align itself with current investment trends in artificial intelligence [1], [2].
The company announced the rebrand on May 28, 2024 [3]. Following the announcement, the stock price jumped almost 40% [3].
Rocket One aims to develop computing systems capable of operating in the harsh environment of space. These systems are designed for low power consumption and tolerance to radiation, which is critical for satellite and defense hardware [1], [2].
As part of this strategic transition, the company is seeking to utilize the AMD AI Developer Program [1]. This partnership is intended to provide Rocket One with resources for advancing software modeling and simulation, which are necessary for the development of space-grade AI chips [1], [2].
The pivot comes as retail investors show increased interest in the intersection of AI and space exploration [2]. By changing its business model, the company is moving away from its previous focus on therapeutics to chase the "AI space dream" [2].
Rocket One will now operate under the ticker RKTO as it pursues these new orbital computing markets [1], [2].
“Hoth Therapeutics is rebranding as Rocket One to focus on low-power, radiation-tolerant AI chip infrastructure.”
The transition from a biotech firm to a space-AI hardware company is a drastic strategic pivot. By aligning with the AI and space-tech trends, Rocket One is attempting to reposition itself for a different class of investors and government defense contracts, moving away from the long and risky clinical trial cycles typical of the pharmaceutical industry.
